Circadian owns Vegenics

By Dylan Bushell-Embling
Thursday, 14 August, 2008

Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.

Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.

Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.

Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.

Content from other channels on our network

UTS pilot project to mitigate methane emissions

Government invests $1.5m in regional science partnerships

Desalination marine works conclude at Belmont

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Sale of Hobart Private Hospital to Calvary raises concerns

Opinion: The growing risk of AI-driven self-diagnosis in breast health

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

APPEX 2027: The Industry Event Powered by APPMA Returns to Melbourne

From bottleneck to backbone: rethinking water in F&B manufacturing

Barry Callebaut appoints new Chief Operating Officer

Arnott's Group celebrates its suppliers at Sydney event

Record growth for food and grocery manufacturing sector, AFGC reports

Circadian owns Vegenics

Scientists uncover how cancer cells hide from immune system

Vanillin flavouring in vapes may disrupt embryo development

Heart valve tissues created from stem cells

Content from other channels on our network